Intellia TherapeuticsNTLA +4.05%70 Current Ratio is 6.10 as of Mar. 2026, which is 24% below its 10-year median of 8.07. GuruFocus rates NTLA with a GF Score™ of 70/100 and a GF Value™ of $20.65 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Intellia Therapeutics ranks better than 63.84% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Intellia Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 6.10.
Intellia Therapeutics has a current ratio of 6.10. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Intellia Therapeutics's Current Ratio or its related term are showing as below:
NTLA'
s Current Ratio Range Over the Past 10 Years
Min: 4.9 Med: 8.07 Max: 14.01
Current: 6.1
During the past 12 years, Intellia Therapeutics's highest Current Ratio was 14.01. The lowest was 4.90. And the median was 8.07.
NTLA's Current Ratio is ranked better than 63.84% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs NTLA: 6.10
Intellia Therapeutics (NAS:NTLA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Intellia Therapeutics Current Ratio Related Terms
Intellia Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Intellia Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTLA vs AUPH, OCUL, VRDN: Current Ratio Comparison
For the Biotechnology subindustry, Intellia Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a Current Ratio of 6.10 as of Mar. 2026. This is 24% below median its historical median of 8.07. Over the past decade, Intellia Therapeutics' Current Ratio has ranged from 4.90 to 14.01. According to the industry distribution chart, Intellia Therapeutics ranks #511 out of 1413 companies in the Biotechnology industry, placing it in the top 36.2%.
Is Intellia Therapeutics' Current Ratio too high?
Intellia Therapeutics' current Current Ratio of 6.10 is 24% below median its 10-year median of 8.07. Over the past 10 years, this metric has ranged from a low of 4.90 to a high of 14.01. The Biotechnology industry median Current Ratio is 3.89. Intellia Therapeutics' value of 6.10 is 56.8% above this industry median. Based on the distribution chart, Intellia Therapeutics ranks #511 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Current Ratio compare to AUPH and OCUL?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #511 out of 1413 companies for Current Ratio. This puts Intellia Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.89. Intellia Therapeutics' value of 6.10 is 56.8% above this benchmark. Historically, Intellia Therapeutics' own Current Ratio has ranged from 4.90 to 14.01 over the past decade. While the company's 10-year median is 8.07 vs. the industry median of 3.89, Intellia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intellia Therapeutics's current Current Ratio of 6.10 is 56.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intellia Therapeutics's current Current Ratio is 6.10, which is 24% below median its own 10-year median of 8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.65, compared to a current price of $16.66 — trading 19.3% below its estimated fair value. The current Current Ratio is 6.10, which is 24% below median its 10-year median of 8.07 and 56.8% above the Biotechnology industry median of 3.89. Intellia Therapeutics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current Current Ratio is 6.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued.
The current stock price of $16.66 is trading 19.3% below its estimated GF Value™ of $20.65.
GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.
Key valuation signals for NTLA:
Current Ratio: 6.10 (24% below median its 10-year median of 8.07)
GF Value™: $20.65 vs. price of $16.66 (19.3% below fair value)
Industry Position: 56.8% above the Biotechnology median (#511 of 1413)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
